{"input_url":"https://www.163.com/dy/article/L22LK5R205349C3G.html","gnews_decode":"https://www.163.com/dy/article/L22LK5R205349C3G.html","http_status":200,"final_url":"https://www.163.com/dy/article/L22LK5R205349C3G.html","html_length":135213,"trafilatura_result":"ok","text_length":5991,"text_preview":"近期，全球多肽和寡核苷酸领域迎来系列进展。Rhythm Pharmaceuticals宣布，评估黑皮质素4受体（MC4R）激动剂setmelanotide治疗获得性下丘脑性肥胖患者的关键性3期TRANSCEND试验结果已发表于《新英格兰医学杂志》（NEJM）。ITM Isotope Technologies宣布，在研放射性治疗药物¹⁷⁷Lu-edotreotide（ITM-11）对比依维莫司（everolimus）治疗晚期胃肠胰神经内分泌肿瘤（GEP-NETs）患者的3期COMPETE研究主要结果发表于《柳叶刀》。此外，Arnatar Therapeutics宣布，其潜在“first-in-c","verdict":"OK"}